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It  is  now  well  known  that  the  presence  of transplantation  antigens  capable  of 
eliciting a  rejection  response in syngeneic hosts on tumor cells is dependent on the 
cause of the tumoral transformation. Most mouse tumors induced by viruses or by 
carcinogens like methylcholanthrene carry strong transplantation antigens (1). On the 
other hand, mouse tumors obtained without explicit experimental interference usually 
show little or no immunogenicity (2, 3). 
We reported that, upon treatment of a nonimmunogenic malignant mouse terato- 
carcinoma cell line with a mutagen, we obtained immunogenic variant cells that were 
incapable  of forming tumors  in  syngeneic mice  (tum-). t  These  variants  undergo a 
process of immune rejection and confer a  long-lasting immunity (4).  Cross-immuni- 
zation  patterns  observed  in  vivo indicate  that  they carry singular  transplantation 
antigens  (5).  Moreover,  mice  that  have  rejected  these  tum-  variants  are  partially 
resistant  to a  challenge with the original teratocarcinoma cells that were capable of 
forming progressive tumors in syngeneic mice (tum+), even though no protection can 
be  induced  either  with  irradiated  tum+  cells  or  with  living  tum+  cells  injected 
subcutaneously and later removed by surgery (6).  The results obtained with terato- 
carcinoma have been extended  to a  Lewis lung carcinoma cell  line:  tum-  variants 
with similar properties have been obtained after mutagenesis (7). 
To analyze the mechanism of the immune rejection of tum- variants, we considered 
that  it  would be  useful  to obtain such  variants  in  an  ascitic tumor cell  line.  This 
should  allow  for  a  better  monitoring of the  tumor  cells  and  the  effectors  of the 
rejection process, as both should be recoverable from the peritoneal cavity. We report 
here  that  we  have obtained  turn-  variants  from  mastocytoma P815-X2,  a  weakly 
antigenic ascitic tumor cell  line derived from a  tumor induced with methylcholan- 
threne  in  mouse strain  DBA/2  (8).  Cross-immunization experiments  performed in 
vivo indicate that some of these variants carry singular transplantation antigens.  In 
the  accompanying report,  we show that singular antigenic specificities can also be 
demonstrated in vitro on these tum- variants by T  lymphocyte-mediated cytolysis. 
Materials and Methods 
Animals.  DBA/2 mice were  derived  from  breeders  obtained from J.  L. Gu~net  (Institut 
Pasteur, Paris). The mice used in the experiments  were between 8 and 12 wk old. 
* Fonds National de la Recherche Scientifique, Brussels, Belgium. 
Abbreviations used in this paper: rum  +, variant ceils that were capable of forming progressive tumors in 
syngeneic mice; turn-, variant cells that were incapable of forming progressive tumors in syngeneic mice. 
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Cells and Culture Conditions.  Our P815 subline was P815-X2. From this permanent line, we 
isolated a  malignant clone called P1  by a  limiting dilution procedure. The P815  cells were 
cultured in  Petri  dishes  (Falcon  1001; Falcon Labware,  Div.  of Becton,  Dickinson & Co., 
Oxnard, Calif.)  in Dulbecco's modified Eagle's medium (1600; Grand Island Biological Co., 
Grand Island, N. Y.) supplemented with 10% fetal calf serum, in an 8% COs atmosphere. 
Mutagenesis.  The cells were incubated with N-methyl-N'-nitro-N-nitrosoguanidine  (Aldrich 
Europe, Beerse, Belgium) at a concentration of 3 #g/ml in Earle's medium at 37°C in an 8% 
CO2 atmosphere for 10 min. This medium was replaced by the culture medium described above 
and the cells were grown for 10 d. The cells were then cloned by a limiting-dilution  method in 
culture medium supplemented with 30% fetal calf serum. The fraction of the cells that survived 
the  mutagenesis was  estimated  to  be 0.2% by extrapolating to  day 0  the  number of cells 
obtained at day 10 in the exponentially growing culture. 
Injections of Cells and Tumor Analysis.  Cells were  injected intraperitoneally in medium that 
contained no fetal  calf serum. The mice were examined every 3 d. They were  considered as 
definitely positive and killed when the volume of tumor ascites was =5 ml. Mice that showed 
no sign of tumor growth after 3 mo were considered negative. 
Adoptive Transfer.  Spleens were teased in Hanks' balanced salts solution supplemented with 
1% fetal calf serum. Cell suspensions were filtered through a nylon-mesh gauze (80 #m; Nylon 
Swiss; Staniar, Manchester, England). The cells were centrifuged and resuspended in Eagle's 
medium with  1% serum and injected in a  vol of 0.3 ml intraperitoneally into mice that had 
been given 700 rad of gamma irradiation a  few hours before.  The reconstituted mice were 
challenged with tumor cells 4 d later. 
Collection and Colony Assay of Intraperitoneal P815 Cells.  Mice were injected intraperitoneally 
with  3  ml  of Eagle's  medium. A  0.3-ml  sample of intraperitoneal fluid was  immediately 
collected with a syringe and put in a tube that contained 6 U of heparin. The cells were diluted 
in Eagle's medium that contained 1% fetal calf serum. Aliquots of 0.2 ml were mixed in a Petri 
dish (Falcon 1007) with 2 ml Eagle's medium that contained 10% fetal calf serum and 0.4% 
Bactoagar (Difco Laboratories, Detroit, Mich.). After a  3-d incubation at 37°C, the colonies 
that contained more than six cells were counted. The number of living intraperitoneal P815 
cells was estimated taking into account a cloning efficiency of ~0.3. 
Results 
We isolated a clone (P1) from the P815 mastocytoma subline P815-X2. This clonal 
line was maintained permanently in vitro. Its doubling time was -10.5 h. When P1 
cells in culture were injected intraperitoneally into the syngeneic DBA/2 mice, they 
regularly produced ascitic tumors at doses as low as 60 cells (Table I). 
High Frequency of turn-  Cells in a Mutagenized P815 Population.  P 1 cells were treated 
with the mutagen N-methyl-N'-nitro-N-nitrosoguanidine  in conditions that  allowed 
for  the  survival of 0.2%  of the  cells.  10  d  later,  the  mutagenized population was 
cloned. 76 clones were injected intraperitoneally into DBA/2 mice at  a  dose of 600 
cells/mouse.  11  clones (14%)  showed a  decreased tumorigenicity: they formed either 
no tumor or occasional tumors that  progressed much more slowly than the control 
tumors.  The inability of these  turn- clones to  form  tumors in syngeneic mice was 
confirmed in numerous experiments. They failed to produce tumors even when the 
injection dose was  1,000 times higher than a dose that regularly allowed the P1 turn  ÷ 
cells to form tumors. The results obtained with seven turn- clones are shown in Table 
I. 
To  check  that  the  appearance  of turn- clones was  a  result  of the  mutagen, we 
injected 17 untreated control clones of P1. All these clones formed progressive tumors 
in all the mice. 
The inability to form tumors in syngeneic mice is a stable characteristic, unaffected 
by 3  mo of continuous culture. In vitro, the turn- clones have the same generation UYTTENHOVE, VAN SNICK, AND  BOON 
TASLE  I 
Tumors Produced by turn  + and tum- P815 Cells in D BA/ 2 Mice 
Cell clone  Dose 
No. mice with tumors/No, mice in- 
jected 
Unirradiated mice*  Irradiated mice* 
P1 (turn +)  6 ×  104  23/24  (33):1:  28/28 (15)~ 
6 ×  102  109/116 (36)  47/51  (17) 
60  19/20  (30)  28130 (19) 
P21  6 ×  104  0/21  20/20 (16) 
6 x  102  2/55  (114)  53/61  (22) 
P32  6 x  104  1/20  (80)  20/20 (15) 
6 ×  102  4151  (37)  40143 (19) 
P35  6 ×  lO  4  0/20  20/20 (15) 
6 ×  102  0/52  69/70 (23) 
P60  6 ×  lO  4  2/20  (41)  23/23 (15) 
6 x  102  1/32  (98)  21/21  (21) 
P76  6 x  104  10/41  (54)  24/24 (17) 
6 x  102  15/42  (46)  20/20 (21) 
P89  6 x  104  2/19  (58)  24/24 (16) 
6 x  102  2/31  (62)  21/21  (21) 
P91  6 x  104  1/22  (80)  23/23 (i6) 
6 ×  102  0/32  20/21  (21) 
1177 
* Normal  adult  mice  (unirradiated)  and  mice  given  700  rad  of gamma 
radiation 3-6 h earlier (irradiated)  were injected intraperitoneally  with living 
P815 cells. These data were pooled from all the injections performed in 1977, 
1978, and 1979. 
~: The average number of days after injection at which the mice display acute 
peritoneal swelling caused by the ascitic tumor is shown in parentheses. 
time as P1  and their morphology is identical. The karyotype of the turn- clones does 
not differ significantly from that of P 1, which has a  major population of cells with 42 
telocentric and one metacentric chromosome. 
Rejection  of the  turn-  Variants.  The  tum-  variants  invariably produced  tumors  in 
mice that  had  received  700  rad  of gamma  radiation  (Table  I).  This suggested  that 
their  inability to  form  tumors  in  normal  mice  was  a  result  of an  immunological 
rejection process. 
To follow the fate of P815 cells injected intraperitoneally, we repeatedly collected 
samples from the peritoneal cavity of the same mouse and estimated  the number  of 
viable tumor cells with a  colony assay (Materials and Methods). The results obtained 
in an experiment involving turn  + clone P1  and turn- clones P21  and P35  are shown 
in Fig.  1. We have chosen three representative mice that were injected with 6,000 cells 
for each clone: two normal and one irradiated. 
In the irradiated mice, both the tum+ and the turn- cells multiplied exponentially 
to reach a  number of ~  108 cells by day  10 after injection. Later,  the number  of cells 
continued to increase, and the animals usually died between day  15 and 20. 1178  IMMUNOGENIC  VARIANTS  OBTAINED  BY  MUTAGENESIS  OF  P815.  I. 
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FIG.  1.  DBA/2 mice were injected intraperitoneally with 6  ×  103 living P815 tum÷ (P1)  or turn 
(P21,  P35)  cells.  At  various times  thereafter, samples  of the  intraperitoneal fluid  were collected 
(Materials and  Methods)  and  the  number of living P815  cells  was estimated  in  an  agar colony 
assay. Each curve represents, on a  logarithmic scale, the number of living P815 cells found in  the 
same mouse that was tapped on the days indicated on the abscissa. The lowest number of cells that 
can be  estimated in  the colony assay is  100.  Points  <100  indicate that  no colony was observed. 
Some curves are interrupted before the last day mentioned on the abscissa because of death caused 
by the tumor. 0, normal mice. O, mice given 700 rad of gamma radiation 3-6 h before injection. 
When unirradiated  mice were injected with turn + cells, some showed a  multiplica- 
tion of tumor cells similar to that found in irradiated mice. These mice died early. For 
others, a decrease in the number of tumor cells was observed starting between  day  I0 
and  15. This decrease was very variable from one mouse to another. In some mice, the 
number  of  tumor  cells  dropped  to  <105 .  However,  the  number  of  tumor  cells 
invariably  rose again  and  the  mice  died.  It  appears,  therefore,  that  the  tum +  cells 
underwent  a  partial  rejection  in some DBA/2  mice. 
In the unirradiated  mice injected  with turn- variants  P21  and P35, the fate of the 
tum-  cells  was  quite  constant:  between  day  10  and  15,  a  rapid  and  complete 
elimination of the tumor cells in all the mice occurred. No tumor cell reappeared later 
and all the mice survived.  During the rejection phase, there was an ~  10-fold increase 
in  the  number  of lymphocytes  and  macrophages  present  in  the  peritoneal  cavity. 
Similar results were obtained with other tuna- variants. 
Immune Protection against turn-  Variants.  Mice that rejected a  first injection of living 
or  irradiated  turn-  cells  acquired  a  radioresistant  immune  protection  against  a 
challenge  with  the  immunizing  clone  and other  turn-  clones  (Table  II).  It  was  also 
possible  to transfer  adoptively  the protection  to  irradiated  animals with spleen  cells 
from immune donors  (Table III). 
These experiments  were used  to analyze the pattern  of immune protection.  There 
was  a  significant  cross-protection  between  all  the  variants.  In  addition,  the  mice UYTTENHOVE, VAN SNICK, AND BOON 
TABL~  II 
Tumors Produced in DBA/ 2 Mice Immunized with turn- Cells 
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Experi- 
ment 
Immunizing 
clone* 
Percentage  of mice with tumors:]:; challenging clone 
P21  P32  P35  P89  P91 
III 
IV 
V 
P21 living  0 (0/10)§  50 (6/12) 
P32 living  14 (1/7)  18 (2/11) 
None  100 (11/11)  I00 (10/10) 
P21 living  0 (0/10)  20 (2/10) 
P91 living  25 (2/8)  0 (0/11) 
None  100 (8/8)  100 (10/10) 
P21 irradiated  8 (1/13)  86 (12/14) 
P35 irradiated  50 (6/12)  30 (3/10) 
None  71 (10/14)  64 (9/14) 
P21 irradiated  7 (1/15)  60 (9/15)  38 (6/16)  25 (3/12) 
P32 irradiated  40 (6/15)  58 (7/13)  73 (t 1/15)  27 (4/15) 
P35 irradiated  67 (10/15)  87 (13/15)  21 (3/14)  38 (3/8) 
P91 irradiated  64 (9/14)  71 (10/14)  50 (7/14)  7 (1/14) 
None  100 (9/9)  100 (8/8)  86 (6/7)  100 (8/8) 
P21 irradiated  0 (0/15)  85 (I2/14)  40 (6/15) 
P89 irradiated  54 (7/13)  30 (4/13)  23 (3/13) 
P91 irradiated  40 (6/15)  93 (14/15)  6 (1/15) 
None  93 (14/15)  93 (14/15)  100 (16/16) 
* Mice were injected intraperitoneally  with 2 ×  105 living turn- cells (experiments I and II) or with 6 ×  l0  s 
cells killed with 10,000 rad of gamma radiation from a Cs source (experiments  III, IV, and V). Control 
mice received the same amount of injection medium. 
z~ 3 wk after immunization, the mice were irradiated with 700 rad and challenged with 2,000 cells injected 
intraperitoneally. 
§ The No. mice with tumors/No, mice injected is shown in parentheses. 
immunized with variants P21,  P35, and  P91  rejected preferentially the immunizing 
variant. The converse was true: the best protection against each of these three variants 
was  observed  in the  mice  that  had  been immunized  with  the  challenging variant. 
These results indicate that in addition to one or more common antigens shared by all 
tum-  variants, a  singular transplantation antigen is present on each of variants P21, 
P35,  and  Pgl.  No evidence for  such  a  singular antigen was  obtained with  variants 
P32 and P89. 
Cross-Protection  against  the  Original  P1  turn  ÷  Clone.  Even  though  we  occasionally 
observed a  partial rejection of the turn  + P1  cells in the peritoneal cavity, we did not 
find any significant immune protection after immunization with irradiated tum÷ cells 
(Table  IV).  It  was  therefore  of interest  to  examine whether  mice  immunized  with 
tum-  variants  were  protected  against  P1.  As  shown  in  Table  IV,  a  significant 
protection  was  conferred  by  living  turn-  variants,  and  even  by  some  irradiated 
variants.  This  protection  was  not  abolished  by  irradiating the  immune  mice.  This 
implies that  at  least  some of the common  antigens present  on the  turn-  clones are 
already present on the original tum÷ cell. 1180  IMMUNOGENIC  VARIANTS  OBTAINED  BY  MUTAGENESIS  OF  P815.  I. 
TABLE  III 
Tumors Produced  in DBA/2 Mice Protected  by Adoptive Transfer 
Experi- 
ment 
Clones used 
~rimmuni- 
zation ofdo- 
nor mice* 
Percentage of mice with tumors:~; challenging clones 
P21  P32  P35  P89  P91 
III 
P21  0 (0/12)§  58 (7/12)  83 (10/12) 
P32  33 (4/12)  44 (4/9)  64 (7/11) 
P35  56 (5/9)  50 (6/12)  18 (2/11) 
None  100 (12/12)  100 (12/12)  100 (12/12) 
P21  0 (0/12)  50 (6/12)  8 (1/12) 
P89  0 (0/12)  0 (0/12)  0 (0/11) 
P91  73 (8/11)  i00 (11/I 1)  0 (0/12) 
None  100 (12/12)  100 (12/12)  100 (12/12) 
P21  58 (7/12)  100 (12/12)  83 (10/12)  75 (9/12) 
P32  92 (I 1/12)  83 (10/I2)  i00 (12/12)  100 (I I/1 I) 
P35  82 (9/1 t)  92 (11/12)  50 (6/12)  64 (7/l 1) 
P91  64 (7/11)  100 (t2/12)  75 (9/12)  44 (4/9) 
None  75 (9/12)  83 (10/12)  92 (11/I2)  100 (12/12) 
* DBA/2 mice were immunized intraperitoneally with 2 ×  10  ~ living rum- cells or with injection medium. 
3 wk later, their spleen cells were collected and used to reconstitute irradiated  DBA/2 recipients. The 
number of spleen cells transferred to the recipients was  1.3  ×  10  7  in experiment I  and  II;  and  106 in 
experiment III. 
:~ DBA/2  mice were  irradiated  with  700  rad  and reconstituted  intraperitoneally a  few hours later with 
immune or normal spleen cells. 4 d later, they were challenged intraperitoneally with 2 ×  10  s living rum- 
cells. 
§ The No. of mice with tumors/No, of mice injected is shown in parentheses. 
Discussion 
By treating mastocytoma PS15-X2 with a  mutagen, we were able to obtain stable 
cell variants that failed to form tumors in the syngeneic mice even when the injection 
dose was  1,000-fold higher than  the minimal  tumorigenic dose of P815. These turn- 
variants multiplied rapidly for ~  10 d  in the peritoneal cavity and reached a number 
of ~ 107 cells. Shortly after that,  the tum- cells disappeared  completely within a  few 
days.  No tumor recurrence occurred for at  least  3 too. The elimination  of the turn- 
variants was immunological in nature  as indicated by its radiosensitivity and by the 
presence  of specific  memory cells  in  the  spleen.  These  results  are  similar  to  those 
observed  previously  with  teratocarcinoma  and  Lewis  lung  carcinoma  cells  treated 
with  the same  mutagen  (4,  7).  Therefore,  it  seems  likely that  tum-  variants  can be 
obtained by mutagenesis of any mouse tumor cell line. 
Cross-immunization experiments  performed either directly or by adoptive transfer 
clearly showed a preferential rejection of the immunizing variants for three of the five 
tum-  clones  that  were  tested.  This  implies  that  each  of these  three  variants  has 
acquired a singular transplantation  antigen. Similar results have been obtained in the 
teratocarcinoma  and  Lewis  lung  carcinoma  systems  (5,  7).  In  addition,  the  cross- 
reactions  indicated  the  presence  of an  antigen  that  is  common  to  the  five  turn- 
variants  and  to  the  tum+  cells.  No  specific  transplantation  antigen  was  found  on 
variants P89 and P32. No such variant had been observed in the two previous systems. 
This may be because P815 is more immunogenic than the two other tumors as shown UYTTENHOVE,  VAN SNICK, AND BOON 
TAaL~  IV 
Protection against tum÷ Cells 
Experi- 
ment 
Immunizing cell* 
Type  Dose 
Percentage of mice 
with tumors* 
P2t  6 x  102  58 (11/19)§ 
2 x  105  50 (9/18) 
P32  6 x  102  60 (12/20) 
2 X  105  22 (4/18) 
None  100 (20/20) 
PI irradiated  6 X 106  93 (15/16) 
P21 living  2 X I05  50 (8/16) 
P21 irradiated  6 ×  106  81 (13/16) 
P35 living  2 ×  105  43 (7/16) 
P35 irradiated  6 X 106  87 (14/16) 
P89 living  2 x  10  ~  0 (0/16) 
P89 irradiated  6 ×  106  50 (8/16) 
None  84 (27/32) 
* DBA/2 mice were injected  intraperitoneally with  living cells or with cells 
killed with  10,000 rad of gamma radiation. Control mice were injected with 
the same amount of culture medium. 
:~ 23 d after immunization,  the mice were challenged  intraperitoneally with 
600 living turn ÷ P1 cells. 
§ No. mice with tumors/No, mice injected is shown in parentheses. 
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by the partial rejection of turn ÷ cells. A  small increase in the immunogenicity of the 
initial antigen may be sufficient to obtain turn- variants. We present in the accom- 
panying report  (9)  an  analysis of the T  lymphocyte-mediated cytolysis against the 
P815  tum- variants described here. This analysis shows the existence of a  significant 
correlation between the detection of singular specificities in vitro and their presence 
in vivo. 
No  significant  protection  against  a  challenge  with  living  tum+  cells  could  be 
obtained  by immunization  with  irradiated turn +  cells.  However,  a  very significant 
protection was obtained by immunizing with living turn- cells. This was also observed 
with  teratocarcinoma  and  Lewis  lung  carcinoma  turn-  variants.  With  some  P815 
turn-  clones,  a  significant  protection  was  also obtained  with  irradiated turn-  cells. 
Similar observations have  been  reported with  xenogenized  tumor cells obtained by 
viral infection (10) or by treatment with chemical compounds  (11). 
A  remarkable aspect of the turn-  variants is their extremely high  frequency after 
mutagenic  treatment.  It  is  at  least  four  orders  of magnitude  higher  than  that  of 
metabolic  mutations  like azaguanine  resistance.  To  our  knowledge,  the only other 
instance where similar frequencies  have been  described involves myeloma cell lines 
that  produce  antibodies with  an  altered  heavy  chain  (12,  13).  If one  assumes  the 
cellular genome to have a  uniform sensitivity to the rnutagen, the genetic target that 
determines  the  rum-  character  on  P815  can  be  estimated  to  be  >2.5%  of  that 
governing the ability to multiply in vitro. The involvement of hypermutable regions 
may represent a  more plausible alternative. On  the basis of this high  frequency, we 
believe that  there is a  definite possibility that  the antigenicity of tumors caused  by 1182  IMMUNOGENIC VARIANTS OBTAINED  BY MUTAGENESIS  OF  P815. I. 
chemical carcinogens is caused by a  mutation  that  is completely independent  from 
that causing the tumoral transformation. 
Summary 
We have reported that it is possible to obtain variants that are incapable of forming 
progressive  tumors  in  syngeneic  mice  (turn-)  by  mutagenesis  and  cloning  of  a 
teratocarcinoma  and  a  Lewis  lung  carcinoma  cell  line.  These  observations  were 
extended to the ascitic P815 mastocytoma of mouse strain DBA/2. After a  treatment 
with  the  mutagen  N-methyl-N'-nitro-N-nitrosoguanidine,  we  obtained  a  high  fre- 
quency  (14%)  of tum- clones. A  colony assay indicated  that  after a  period  of rapid 
multiplication  extending to ~  10 d  after injection, the P815 turn- cells were rejected 
by a  process  that  was  usually  completed  by day  15.  No rejection  was  observed  in 
sublethally irradiated animals. The immunological nature of the rejection of the P815 
variants was further inferred because, upon rejection, the mice acquired a radioresist- 
ant specific protection that could be transferred adoptively with spleen cells. 
Cross-immunization patterns demonstrated the presence of singular antigenic spec- 
ificities  on  three  of the  five  variants  that  were  examined.  In addition,  a  common 
antigen  was found on all the turn- variants and the original cells that were capable 
of forming progressive  tumors  in  syngeneie  mice  (turn+).  Mice  injected  with  turn- 
cells were significantly protected against a turn ÷ challenge, even though no significant 
protection  was  generated  by  irradiated  turn +  cells.  A  study  of the  T  lymphocyte- 
mediated  cytolysis  against  the  P815  variants  described  here  is  presented  in  the 
accompanying report  (9). 
We thank Paul Wauters, Martine Marchand, and Marie Marchand for their contribution to 
the experiments; Guy Warnier for the production of experimental mice; and A. Van Pel for her 
advice. 
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